Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/23/2026 07:18 PST] upb Expected to Trade Up After Bullish Patterns Develop
• [02/13/2026 12:42 PST] Upstream Bio, Inc. (NASDAQ:upb), Down By 100% ($12.8) From $12.8 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [02/13/2026 07:53 PST] upb Expected to Trade Down After Bearish Patterns Develop
• [01/20/2026 07:11 PST] upb Expected to Trade Down After Bearish Patterns Develop
• [01/14/2026 07:45 PST] upb Expected to Trade Up After Bullish Patterns Develop
• [01/13/2026 07:16 PST] upb Expected to Trade Up After Bullish Patterns Develop